A novel CD47-blocking checkpoint inhibitor has shown promising interim results in a multicenter Phase I trail for relapsed/refractory mycosis fungoides…
Browsing: Lymphoma
Precision medicine is improving outcomes, toxicity and disease management in trials and routine clinical practice. Anas Younes, MD, from the…
In this session, Thomas Habermann, MD, of the Mayo Clinic, Rochester, MI, chairs a discussion with Bjoern Chapuy, PhD, MD,…
Immunotherapy is at the forefront of research into novel treatments for lymphoma. Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed…
CAR T-cells are a hot topic right now, with huge potential for transforming the treatment of various hematological malignancies, including…
Lymphoma treatment is focusing increasingly on novel agents with specific targets. At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018…
CAR T-cells have the potential to revolutionize the field of hematological oncology, however despite impressive efficacy data from CAR T…
Axicabtagene ciloleucel, an anti-CD19 CAR T-cell product, has shown impressive efficacy in diffuse large B-cell lymphoma already. In this video,…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, John Rossi, MS, from Kite…
Nathan Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of minimal residual…
Patients that relapse or are resistant to treatments are classified as high-risk in follicular lymphoma. Here, Nathan Fowler, MD, of…
In this interview, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal,…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Andrés Ferreri, MD,…
Dividing patients into subgroups for different therapies can often be quite difficult. In this interview, recorded at the 2018 European…
Martin Hutchings, MD, PhD from Copenhagen University Hospital, Copenhagen, Denmark, discusses current first-line treatment options in Hodgkin lymphoma at the…
Dr Olivier Casasnovas, from the Department of Hematology, Dijon, France, gives an update on data from the Phase III AHL2011…
Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenströms macroglobulinemia (WM) were presented at…
“Dr Laurie Sehn, of the BC Cancer Agency, Vancouver, BC, Canada presents: ‘Answering the unmet need in one of the…
Dr Franck Morschhauser, of Centre Hospitalier Universitaire Régional de Lille, Unité GRITA, Lille, France, discusses the question: is RELEVANCE relevant?…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Raúl Córdoba, MD, PhD, MS,…
Patients with T-cell leukemias typically have a worse prognosis than those with B-cell malignancies. In this interview, Kimberly Dunsmore, MD,…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Raúl Córdoba, MD, PhD, MS,…
In this interview, Raúl Córdoba, MD, PhD, MS, of the Fundacion Jimenez Diaz University Hospital, Madrid, Spain, discusses the problems…
BTK inhibitors like ibrutinib have shown impressive efficacy in treating mantle cell lymphoma (MCL) in the first relapse setting; however,…
BTK inhibition is a popular avenue of treatment research in Waldenström’s macroglobulinemia (WM). In this video, recorded at the 23rd…
Patients with relapsed, transplant ineligible diffuse large B-cell lymphoma (DLBCL) face extremely poor outcomes. In this video, recorded at the…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Simon Rule, MD, of…
Mantle cell lymphoma (MCL) outcomes have improved in recent years as a result of an influx of improved treatments, including…
Follicular lymphoma treatments are improving; however, there are subgroups of patients who still have poor outcomes. Here, Marek Trneny, MD,…
In relapsed/refractory diffuse large B-cell lymphoma (DLBCL), response rates are poor for salvage treatments and autologous stem cell transplants. Here,…
Chemotherapy is ineffective against a certain subset of diffuse large B-cell lymphoma (DLBCL) types. In this video, recorded at the…
Cutting-edge trial data in the field of lymphoma was presented at the American Society of Oncology (ASCO) 2018 Annual Meeting…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Nathan Fowler, MD, of the MD…
Results of the Phase III RELEVANCE trial (NCT01476787) of rituximab-lenalidomide for untreated follicular lymphoma were presented at the American Society…
Currently, CAR T-cell products are primarily tested in the relapsed setting. However, bringing these novel agents to patients earlier in…
CAR T-cell monotherapies have produced promising results; however, the duration of remission needs to be optimized. Here, Jeremy Abramson, MD,…
CAR T-cells represent an exciting new treatment frontier across a variety of blood cancers. We interviewed David Maloney, MD, PhD,…
BTK inhibitors have seen success in treating various hematological malignancies, and their approval has been extended to mantle cell lymphoma…
Ramon Garcia-Sanz, MD, PhD from the University Hospital of Salamanca, Salamanca, Spain, shares exciting data in Waldenströms macroglobulinemia (WM) from…
Stem cell transplants are one of the most well-studied and effective therapies for blood cancers. In this video, Anna Sureda,…
While the current frontline ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen for treating advanced-stage Hodgkin lymphoma is effective with manageable side…
In this interview with Arjan Diepstra, PhD, from the University of Groningen, Groningen, Netherlands, speaking from the 23rd congress of…
The tumor microenvironment is an important therapeutic consideration. Here, Stephen Devereux, FRCP, FRCPath, PhD, of Kings College Hospital NHS Foundation…
CAR T-cell therapy has been established as an effective treatment option for a range of hematological cancers. In this video,…
While treatment for follicular lymphoma (FL) has improved in recent years, allowing most patients to have good outcomes, there remains…
The RELEVANCE study (NCT01476787) looks at the ‘R-squared’ regimen that combines lenalidomide and rituximab for the treatment of follicular lymphoma.…
In this video, Raul Cordoba, MD, PhD, outlines the pre-clinical studies that are occurring at the Fundacion Jimenez Diaz University…
The Checkmate 205 study (NCT02181738) is looking at nivolumab in previously treated and newly diagnosed patients with classical Hodgkin lymphoma.…
Difficult multidisciplinary team decisions occur within follicular lymphoma (FL) due to the heterogeneity that exists within the disease. In this…
There have been many promising therapies for lymphoma recently, with several interesting clinical trials in progress or upcoming. In this…